Biocept Raises $2.2 Million from Ally Bridge; Plans China Expansion

01:45 EDT 11 Aug 2017 | ChinaBio Today

Biocept , a San Diego liquid biopsy company, raised $2.2 million from Hong Kong's Ally Bridge LB Healthcare Master Fund in a private placement. Biocept provides physicians with personal medicine tests for cancer treatment, using its Target Selector™ platform to analyze circulating tumor cells and circulating tumor DNA. In addition to the capital, Ally Bridge will help Biocept develop a strategic plan to bring its liquid biopsy platform to China. More details....

Stock Symbol: (NSDQ: BIOC)

Share this with colleagues:

Original Article: Biocept Raises $2.2 Million from Ally Bridge; Plans China Expansion


More From BioPortfolio on "Biocept Raises $2.2 Million from Ally Bridge; Plans China Expansion"

Quick Search

Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...